| Aimmune Therapeutics is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. Co.'s main therapeutic approach, which it refers to as Characterized Oral Desensitized Immunology Therapy (CODIT), is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure or reduce symptom severity should an allergic reaction occur. PALFORZIA (Peanut (Arachis hypogaea) Allergen Powder-dnfp) is Co.'s internally developed product utilizing CODIT and has been approved by the U.S. Food and Drug Administration and it is indicated for the mitigation of allergic reactions. We show 23 historical shares outstanding datapoints in our AIMT shares outstanding history coverage, used to compute AIMT market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AIMT market cap history over the course of time is important for investors
interested in comparing AIMT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AIMT versus a peer is one thing; comparing
AIMT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AIMT can fluctuate over the course of history.
With this page we aim to empower investors researching AIMT by allowing them to research the AIMT market cap history.